80 related articles for article (PubMed ID: 7880102)
1. [The present status and problems of phase III clinical trials of the new anti tumor drug-pharmaceutical company's view].
Yamada A
Gan To Kagaku Ryoho; 1995 Feb; 22(3):323-7. PubMed ID: 7880102
[TBL] [Abstract][Full Text] [Related]
2. [Current status and issues in clinical trials of anticancer agents].
Kojima H
Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():295-301. PubMed ID: 7986107
[TBL] [Abstract][Full Text] [Related]
3. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
4. [The revision of Guidelines for Clinical Evaluation Methods of Anti-Cancer Drugs in Japan].
Andoh M; Fujiwara Y; Shimada Y
Gan To Kagaku Ryoho; 2006 Jul; 33(7):1015-9. PubMed ID: 16878363
[TBL] [Abstract][Full Text] [Related]
5. [Our policy and future tasks related to ICH in anti-cancer drug development--a discussion from the viewpoint of an enterprise].
Ekimoto H
Gan To Kagaku Ryoho; 1997 Jan; 24(2):229-37. PubMed ID: 9030236
[TBL] [Abstract][Full Text] [Related]
6. Clinical trial design in metastatic breast cancer: a commentary.
Levine M
Can J Oncol; 1995 Dec; 5 Suppl 1():40-2. PubMed ID: 8853523
[TBL] [Abstract][Full Text] [Related]
7. [Status quo and problems in phase III trials: view of a trialist].
Hamajima N
Gan To Kagaku Ryoho; 1995 Feb; 22(3):319-22. PubMed ID: 7880101
[TBL] [Abstract][Full Text] [Related]
8. [Development of anti-cancer drugs under new renewed GCP--from the viewpoint of drug development company developer].
Ueno T; Kobayashi T; Inoue K; Yanagi Y; Yamada Y
Gan To Kagaku Ryoho; 1998 Apr; 25(5):663-70. PubMed ID: 9571963
[TBL] [Abstract][Full Text] [Related]
9. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.
El-Maraghi RH; Eisenhauer EA
J Clin Oncol; 2008 Mar; 26(8):1346-54. PubMed ID: 18285606
[TBL] [Abstract][Full Text] [Related]
10. [Principle and practice of clinical phase III studies].
Morant R
Onkologie; 2008; 31 Suppl 2():53-7. PubMed ID: 18487870
[TBL] [Abstract][Full Text] [Related]
11. [Phase III study].
Furuse K
Gan To Kagaku Ryoho; 1995 Apr; 22(5):611-5. PubMed ID: 7717712
[TBL] [Abstract][Full Text] [Related]
12. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
13. Drug research: from the idea to the product.
Kuhlmann J
Int J Clin Pharmacol Ther; 1997 Dec; 35(12):541-52. PubMed ID: 9455711
[TBL] [Abstract][Full Text] [Related]
14. [Participation to international registration trials--from the investigator's standpoint].
Ohtsu A
Gan To Kagaku Ryoho; 2007 Feb; 34(2):297-300. PubMed ID: 17301548
[TBL] [Abstract][Full Text] [Related]
15. Approaches to the development and marketing approval of drugs that prevent cancer.
Kelloff GJ; Johnson JR; Crowell JA; Boone CW; DeGeorge JJ; Steele VE; Mehta MU; Temeck JW; Schmidt WJ; Burke G
Cancer Epidemiol Biomarkers Prev; 1995; 4(1):1-10. PubMed ID: 7894318
[TBL] [Abstract][Full Text] [Related]
16. [Post launch studies].
Akaza H; Ohashi Y; Shimada Y; Ikeda T; Saijo N; Isonishi S; Hirao Y; Tsuruo T; Tsukagoshi S; Sone S; Nakamura S; Kato M; Mikami O; von Euler M; Blackledge G; Milsted B; Vose B
Gan To Kagaku Ryoho; 2002 Nov; 29(11):2037-48. PubMed ID: 12465411
[TBL] [Abstract][Full Text] [Related]
17. Clinical data gap between phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: evaluation of etanercept in rheumatoid arthritis.
Farahani P; Levine M; Gaebel K; Thabane L
Can J Clin Pharmacol; 2005; 12(3):e254-63. PubMed ID: 16278497
[TBL] [Abstract][Full Text] [Related]
18. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems.
Glasser SP; Salas M; Delzell E
J Clin Pharmacol; 2007 Sep; 47(9):1074-86. PubMed ID: 17766697
[TBL] [Abstract][Full Text] [Related]
19. [Review process of new oncology drug application in Japan--role of MD reviewer].
Fujiwara Y
Gan To Kagaku Ryoho; 1999 Jan; 26(2 Suppl):196-203. PubMed ID: 9987519
[TBL] [Abstract][Full Text] [Related]
20. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
Cohen MH; Williams G; Johnson JR; Duan J; Gobburu J; Rahman A; Benson K; Leighton J; Kim SK; Wood R; Rothmann M; Chen G; U KM; Staten AM; Pazdur R
Clin Cancer Res; 2002 May; 8(5):935-42. PubMed ID: 12006504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
